Table 1. Baseline characteristics of 24 communities randomized to either continuation or cessation of biannual mass azithromycin treatment.

	Biannual MDA (N = 12 communities)	No MDA (N = 12 communities)
Persons per community	309 (242–423)	259 (180–360)
Proportion female, %	51.1% (47.6–52.4%)	52.1% (48.6–55.2%)
Proportion <10 years, %	28.3% (26.5–29.5%)	27.2% (25.4–29.8%)
Prevalence of active trachoma, %*	42.1% (13.1–53.6%)	30.9% (20.0–48.9%)
Distance to nearest town, km	8.4 (5.1–9.2)	8.1 (5.0–9.1)
Altitude, m	2622 (2528–2674)	2611 (2545–2657)

Values indicate the median and interquartile range of community-level data. MDA: mass drug administration with azithromycin

* Sub-district prevalence, as assessed from a random sample of children aged <10 years of age